Good morning and welcome to Agenus' third quarter 2024 conference call and webcast. All participants will be in a listen-only ...

November 6, 2024Personalis, Inc. misses on earnings expectations. Reported EPS is $-0.64 EPS, expectations were $-0.33.

Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...

Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange ...

First patient dosed in Phase 1 clinical trial evaluating ZW171 in advanced mesothelin (MSLN)-expressing cancers Preclinical data presented on ...

Investigators report findings from a phase 3 trial demonstrating that transdermal estradiol patches were as effective as luteinizing hormone-releasing hormone agonists.

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell ...

We are well on our way to achieving our 2027 financial target of 15% compounded revenue growth and greater than 20% adjusted EBITDA ... Cologuard so far this year, 24 million patients, more ...

“As we look to the primary endpoint data readout from our Phase 3 pivotal trial in the first half of next year ... $24.0 million, compared to $21.7 million for the three months ended September 30, ...

Greetings, and welcome to the Incyte third-quarter financial results conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to turn ...

Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ETCompany ParticipantsBill Anderson - Chairman & CEOWolfgang Nickl ...

The largest ever clinical trial of T cell therapy (a type of cell-based immunotherapy) for solid tumours has been completed. Led by a Singapore clinician-investigator, the global, international, ...